<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100826">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01914159</url>
  </required_header>
  <id_info>
    <org_study_id>N-037.0156</org_study_id>
    <nct_id>NCT01914159</nct_id>
  </id_info>
  <brief_title>Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study</brief_title>
  <acronym>RIP</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration
      (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical
      trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab
      (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study
      period of 12 months in 30 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal morphology</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Spectral-domain optical coherence tomography (SD-OCT), fundus autofluorescence imaging, fluorescence angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual function quality of life</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual function questionairy 25 (VFL-25)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)</intervention_name>
    <description>Monthly intravitreal injections</description>
    <arm_group_label>Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a pigment epithelial tear secondary to age-related macular degeneration

          -  Written informed consent

        Exclusion Criteria:

          -  Time of diagnosis more than 6 months before study recruitment

          -  Ocular surgery of the study eye within 1 month before study recruitment

          -  Extensive subretinal fibrosis or retinal atrophy of the study eye

          -  Significant opacification of optical media of the study eye

          -  Uncontrolled glaucoma of the study eye

          -  Active ocular inflammation of the study eye

          -  Best-corrected visual acuity of the contralateral eye below 20/200

          -  Concurrent ocular or systemic therapy with other vascular endothelial growth factor
             (VEGF)-inhibitory drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tim U Krohne, MD</last_name>
    <phone>+49/228/287-15505</phone>
    <email>krohne@uni-bonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank G Holz, MD</last_name>
    <phone>+49/228/287-15505</phone>
    <email>frank.holz@ukb.uni-bonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bonn, Department of Ophthalmology</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim U Krohne, MD</last_name>
      <phone>+49/228/287-15505</phone>
      <email>krohne@uni-bonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank G Holz, MD</last_name>
      <phone>+49/228/287-15505</phone>
      <email>frank.holz@ukb.uni-bonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Frank G Holz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tim U Krohne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seleman Bedar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of M端nchen (LMU), Department of Ophthalmology</name>
      <address>
        <city>M端nchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Wolf, MD</last_name>
      <phone>+49/89/5160-3811</phone>
      <email>armin.wolf@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Armin Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tine R Herold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universityof M端nster, Department of Ophthalmology</name>
      <address>
        <city>M端nster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Eter, MD</last_name>
      <phone>+49/251/83-56004</phone>
      <email>eter@uni-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Nicole Eter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph R Clemens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>July 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank G. Holz</investigator_full_name>
    <investigator_title>Director, Department of Ophthalmology, University of Bonn</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
